Recursion Says REC-4881 Cut Total Polyp Burden By Median 47% After 12 Weeks In 15-Patient Single-Arm Phase 2 Familial Adenomatous Polyposis Trial
Share
Why It Matters
Recursion's new medicine reduced colon growths by about half in early testing. This is a promising sign, though the test was small and early stage.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.